scholarly journals Acute Myocardial Infarction in Young Systemic Lupus Erythematosus Patient with Normal Coronary Arteries

Cureus ◽  
2017 ◽  
Author(s):  
Ali Farooq ◽  
Aman Ullah ◽  
Farman Ali ◽  
Hassaan Yasin ◽  
Waseem Amjad ◽  
...  
Angiology ◽  
1990 ◽  
Vol 41 (8) ◽  
pp. 662-666 ◽  
Author(s):  
Kan Takayanagi ◽  
Yuji Nakamura ◽  
Michita Kishimoto ◽  
Hiroshi Ouami ◽  
Seiichi Shibata

2009 ◽  
Vol 36 (3) ◽  
pp. 570-575 ◽  
Author(s):  
MANSI A. SHAH ◽  
AMBER M. SHAH ◽  
ESWAR KRISHNAN

Objective.Systemic lupus erythematosus (SLE) is associated with higher risk for acute myocardial infarction (MI); but the post-infarction outcomes among these patients are unknown. Our objective was to compare post-acute MI outcomes in patients with SLE to those with diabetes mellitus (DM) and those with neither condition.Methods.We analyzed the risk for prolonged hospitalization and in-hospital mortality following acute MI in the 1993–2002 US Nationwide Inpatient Sample. We used logistic regression to calculate odds ratios (OR) for prolonged hospitalization and Cox proportional hazards regression to calculate hazard ratios (HR) for in-hospital mortality with and without adjustments for age, sex, race/ethnicity, socioeconomic status, and presence of congestive heart failure.Results.For the SLE (n = 2192), DM (n = 236,016), SLE/DM (n = 474), and control (n = 667,956) groups, the in-hospital mortality rates were 8.3%, 6.2%, 5.7%, and 4.7%, respectively. In multivariable regression models, all 3 disease groups had higher adverse outcome risk compared to control. The OR for prolonged hospitalization was higher for those with SLE (OR 1.48, 95% CI 1.32–1.79) compared to those with DM (OR 1.30, 95% CI 1.28–1.32). A similar pattern was observed for hazard ratios for in-hospital mortality as well (SLE, HR 1.65, 95% CI 1.33–2.04; DM, HR 1.11, 95% CI 1.07–1.14).Conclusion.SLE, like DM, increases risk of poor outcomes after acute MI. These patients need to be triaged appropriately for aggressive care.


2011 ◽  
Vol 50 (21) ◽  
pp. 2669-2673 ◽  
Author(s):  
Yoshinori Matsumoto ◽  
Hiroshi Wakabayashi ◽  
Fumio Otsuka ◽  
Kentaro Inoue ◽  
Mariko Takano ◽  
...  

1992 ◽  
Vol 15 (3) ◽  
pp. 310-316
Author(s):  
Takahiro Suzuki ◽  
Takao Koike ◽  
Kenji Ichikawa ◽  
Takao Sugiyama ◽  
Katsuhiko Takabayashi ◽  
...  

2020 ◽  
Author(s):  
Mar Pujades-Rodriguez ◽  
Ann W Morgan ◽  
Richard M Cubbon ◽  
Jianhua Wu

ABSTRACTBackgroundEvidence for the association between glucocorticoid dose and cardiovascular risk is weak for moderate and low doses. To quantify glucocorticoid dose-dependent cardiovascular risk in people with six immune-mediated inflammatory diseases.Methods and FindingsPopulation-based cohort analysis of medical records from 389 primary care practices contributing data to the UK Clinical Practice Research Datalink, linked to hospital admissions and deaths in 1998-2017. There were 87,794 patients with giant cell arteritis and/or polymyalgia rheumatica (n=25,581), inflammatory bowel disease (n=27,739), rheumatoid arthritis (n=25,324), systemic lupus erythematosus (n=3951), and/or vasculitis (n=5199); and no prior cardiovascular disease (CVD). Mean age was 56 years and 34.1% were men. Median follow-up time was 5.0 years. Time-variant daily and cumulative glucocorticoid prednisolone-equivalent dose-related risks and hazard ratios of first all-cause and type-specific CVD.We found 13,426 (15.3%) people with incident CVD, including 6,013 atrial fibrillation, 7,727 heart failure and 2,809 acute myocardial infarction events. At 1 and 5 years, the cumulative risks of all-cause CVD increased from 1.5% in periods of non-use to 9.1% for a daily prednisolone-equivalent dose of ≥25.0mg, and from 7.6% to 29.9%, respectively. We found strong dose-dependent estimates for all immune-mediated diseases (hazard ratio [HR] for <5.0mg daily dose vs. non-use=1.74, 95%CI 1.64-1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteritis to 2.82 for systemic lupus erythematosus), all cardiovascular outcomes, regardless of disease activity level. The highest estimates were for heart failure and acute myocardial infarction.ConclusionsWe estimated glucocorticoid dose-dependent cardiovascular risk in six immune-mediated diseases. Results highlight the importance of prompt and regular monitoring of cardiovascular risk and use of primary prevention treatment at all glucocorticoid doses.


Sign in / Sign up

Export Citation Format

Share Document